{"url_path":"/sec/dwtx/8-k/2026-06-17/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-075204-index.html","accession_number":"0001104659-26-075204","cik":"0001818844","ticker":"DWTX","issuer_name":"Dogwood Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818844/0001104659-26-075204-index.html","primary_entity_key":"0001818844","primary_entity_name":"Dogwood Therapeutics, Inc."},"word_count":483,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n​\n\nOn June 16, 2026, the Company held its Annual Meeting. Present at the Annual Meeting in person or by proxy were holders of 31,791,500 shares of common stock of the Company, representing 95.17% of the voting power of the shares of common stock of the Company as of the close of business on April 21, 2026, the record date for the Annual Meeting, and constituting a quorum for the transaction of business. All matters voted upon at the Annual Meeting were approved with the required votes. The following proposals were submitted to a vote of the Company’s stockholders, with the voting results indicated below.\n\n​\n\n**1. Election of Directors.**\n\nThe following seven nominees were elected to serve as directors of the Company, with the following votes tabulated:\n\n​\n\n​\n\n​\n\n**For**\n\n**Withheld**\n\n**Broker Non-Vote**\n\nAbel De La Rosa, Ph.D.\n\n28,684,078\n\n7,501\n\n3,099,921\n\nGreg Duncan\n\n28,682,224\n\n9,355\n\n3,099,921\n\nDavid Keefer\n\n28,680,250\n\n11,329\n\n3,099,921\n\nJohn C. Thomas, Jr.\n\n28,683,680\n\n7,899\n\n3,099,921\n\nMelvin Toh, M.B.B.S.\n\n28,682,093\n\n9,486\n\n3,099,921\n\nRichard J. Whitley, M.D.\n\n28,678,320\n\n13,259\n\n3,099,921\n\nAlan Yu\n\n28,678,659\n\n12,920\n\n3,099,921\n\n​\n\n​\n\n**2. Ratification of the appointment of Forvis Mazars, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.**\n\nThe appointment of Forvis Mazars, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified, with the following votes tabulated:\n\n​\n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Vote**\n\n31,778,192\n\n2,397\n\n10,911\n\n-\n\n​\n\n**3. Approval of the amendment to the Dogwood Therapeutics, Inc. Certificate of Incorporation to increase the number of shares of common stock and preferred stock authorized for issuance.**\n\nThe amendment to the Certificate of Incorporation was approved with the following votes tabulated:\n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Vote**\n\n28,431,012\n\n243,744\n\n16,823\n\n3,099,921\n\n​\n\n2\n\n**4. Advisory vote on the frequency of future advisory votes on named executive officer compensation (“Say-on-Frequency” proposal).**\n\nThe Company’s stockholders approved, by an advisory vote, the Say-on-Frequency proposal, with the following votes tabulated:\n\n​\n\n**One Year**\n\n​\n\n**Two Years**\n\n**Three Years**\n\n**Abstain**\n\n​\n\n**Broker Non-Vote**\n\n​\n\n28,682,394\n\n2,534\n\n3,655\n\n​\n\n2,996\n\n3,099,921\n\n​\n\n​\n\n**5. Advisory vote on the compensation of our named executive officers (“Say-on-Pay” proposal).**\n\nThe Company’s stockholders approved, by an advisory vote, the compensation of its named executive officers, with the following votes tabulated:\n\n**For**\n\n**Against**\n\n**Abstain**\n\n**Broker Non-Vote**\n\n28,662,176\n\n25,962\n\n3,441\n\n3,099,921\n\n​\n\n​\n\nBased upon the results of the stockholder vote on Proposal Four, the Say-on-Frequency proposal, and the Board’s recommendation of “One Year” with respect to said Proposal, the Board has determined that the Company will include a stockholder vote on the compensation of executives in its proxy materials every year, until the next required vote on the frequency of stockholder votes on the compensation of executives as required by Section 14A(a)(2) of the Exchange Act.\n\n​\n\n​\n\n​\n\n​"}